Compare IPCA Labs with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUN PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUN PHARMA IPCA LABS/
SUN PHARMA
 
P/E (TTM) x 38.8 509.5 7.6% View Chart
P/BV x 8.1 3.1 258.1% View Chart
Dividend Yield % 0.1 0.5 29.4%  

Financials

 IPCA LABS   SUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
SUN PHARMA
Mar-19
IPCA LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,042679 153.5%   
Low Rs590375 157.2%   
Sales per share (Unadj.) Rs298.6121.1 246.5%  
Earnings per share (Unadj.) Rs35.013.4 261.7%  
Cash flow per share (Unadj.) Rs49.420.7 239.0%  
Dividends per share (Unadj.) Rs3.002.75 109.1%  
Dividend yield (eoy) %0.40.5 70.5%  
Book value per share (Unadj.) Rs247.1172.6 143.2%  
Shares outstanding (eoy) m126.352,399.26 5.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.74.4 62.8%   
Avg P/E ratio x23.339.4 59.2%  
P/CF ratio (eoy) x16.525.5 64.8%  
Price / Book Value ratio x3.33.1 108.1%  
Dividend payout %8.620.6 41.7%   
Avg Mkt Cap Rs m103,1081,264,650 8.2%   
No. of employees `00013.417.5 76.8%   
Total wages/salary Rs m7,87459,671 13.2%   
Avg. sales/employee Rs Th2,807.016,608.1 16.9%   
Avg. wages/employee Rs Th585.83,409.6 17.2%   
Avg. net profit/employee Rs Th329.01,833.8 17.9%   
INCOME DATA
Net Sales Rs m37,732290,659 13.0%  
Other income Rs m57710,255 5.6%   
Total revenues Rs m38,309300,914 12.7%   
Gross profit Rs m6,90163,076 10.9%  
Depreciation Rs m1,82417,533 10.4%   
Interest Rs m1895,553 3.4%   
Profit before tax Rs m5,46550,246 10.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m1,0426,009 17.3%   
Profit after tax Rs m4,42232,093 13.8%  
Gross profit margin %18.321.7 84.3%  
Effective tax rate %19.112.0 159.5%   
Net profit margin %11.711.0 106.1%  
BALANCE SHEET DATA
Current assets Rs m23,778310,692 7.7%   
Current liabilities Rs m10,975173,396 6.3%   
Net working cap to sales %33.947.2 71.8%  
Current ratio x2.21.8 120.9%  
Inventory Days Days10499 104.8%  
Debtors Days Days66112 59.1%  
Net fixed assets Rs m20,368232,477 8.8%   
Share capital Rs m2532,399 10.5%   
"Free" reserves Rs m30,971411,691 7.5%   
Net worth Rs m31,224414,091 7.5%   
Long term debt Rs m1,40915,226 9.3%   
Total assets Rs m45,507646,938 7.0%  
Interest coverage x30.010.0 298.1%   
Debt to equity ratio x00 122.7%  
Sales to assets ratio x0.80.4 184.5%   
Return on assets %10.15.8 174.1%  
Return on equity %14.27.8 182.7%  
Return on capital %17.310.2 170.4%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30866,025 26.2%   
Fx outflow Rs m6,26638,610 16.2%   
Net fx Rs m11,04227,415 40.3%   
CASH FLOW
From Operations Rs m4,92321,965 22.4%  
From Investments Rs m-1,563-6,813 22.9%  
From Financial Activity Rs m-1,832-27,305 6.7%  
Net Cashflow Rs m1,528-8,442 -18.1%  

Share Holding

Indian Promoters % 45.9 63.7 72.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.1 222.2%  
FIIs % 25.3 23.0 110.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.3 209.6%  
Shareholders   36,892 133,026 27.7%  
Pledged promoter(s) holding % 2.1 0.5 403.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   UNICHEM LAB  AUROBINDO PHARMA  PFIZER  GLENMARK PHARMA  VENUS REMEDIES  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 225 Points Higher; Metal and Banking Stocks Witness Buying(Closing)

Extending gains to the fourth consecutive session, Indian share markets witnessed buying interest throughout the day today and ended higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 11, 2020 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS